tbuckley/cabot-search huggingface dataset:
SELECTIONS.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Media advertising for tobacco products. Board of Trustees reports
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fibronectin isoform gene expression in rat hepatic stellate and parenchymal cells of normal and fibrotic liver . Laboratory for Cell Biology and Histology, (1) Laboratory for Toxicology, Free University Brussels (V.U.B.), and (2) Department of Anatomy, University of Helsinki
Journal: Hepatology (1995)

Improved understanding of the involvement of matrix metalloproteinases (MMPs), including membrane-type MMPs (MT-MMPs), in human tumours has potential diagnostic, prognostic and therapeutic implications. We assessed the relationship between MT-MMP expression and clinicopathological parameters in human non-small cell lung cancer (NSCLC) and histologically normal lung tissue by quantitative Real Time PCR (qRT-PCR). All MT-MMPs (MMPs 14–17, 24 and 25) were detected by qRT-PCR with significantly higher MMP-14, -15 and -17 expression observed in tumour relative to normal lung specimens. MMP-16 was undetectable in normal lung but expressed in 8% tumours. MMP-15 demonstrated significant overexpression in adenocarcinomas relative to squamous cell carcinomas and normal lung tissue. MMP-14 mRNA expression strongly correlated to MMP-14 proteolytic activity in preclinical tumour models, indicating that qRT-PCR may predict MMP-14 activity levels in NSCLC. These data suggest that MMP-14, -15 and -17 may be good markers of disease, or therapeutic targets for treatment of human NSCLC.
OP12 Similar Svr Rates In Il28b Cc, Ct Or Tt prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the Realize Study
Authors: G. R. Foster, S. Pol, J. Aerssens, S. Zeuzem, P. Andreone, E. J. Lawitz, S. Roberts, Z. Younossi, R. Focaccia, A. Horban, P. J. Pockros, R. Van Heeswijk, S. de Meyer, D. Luo, M. Beumont, G. Picchio
Journal: Gut (2011)

<h3>Introduction</h3> IL28B polymorphisms are linked to differences in SVR rates in HCV treatment-naÔve patients treated with pegylated interferon (P) and ribavirin (R). REALIZE is a Phase 3 study that compared the efficacy, safety and tolerability of telaprevir (T), with or without a Lead-in (LI), in combination with PR against PR alone in prior treatment-failure patients including relapsers, partial responders and null responders (NR). Both T/PR arms were superior to control in all three patient categories. The relationship between IL28B genotype and SVR was investigated retrospectively. <h3>Method</h3> 527/662 (80%) patients enrolled in REALIZE consented to genetic testing. This represented 72%, 76% and 98% of the total relapsers, partial responders, and NR, respectively. Genotype rs12979860 was determined using a TaqMan allelic discrimination assay validated against Sanger sequencing on 50 independent samples. This was a retrospective study based on patients who consented to genetic testing prior to the discovery of IL28B, thus, sample size was not based on formal statistical considerations. <h3>Results</h3> Overall, 94% were Caucasian and 4% were Black. 18% of patients were IL28B CC, 61% CT and 21% TT. By prior response category, the highest proportion of IL28B TT patients was among prior NR (28%) while the highest frequency of CC patients occurred among prior relapsers (27%). The observed IL28B genotype frequencies indicate that the population was not in Hardy–Weinberg equilibrium (χ<sup>2</sup>=28, p&lt;0.0001). IL28B genotypes were well balanced across all arms with exception of a higher frequency of TTs in the placebo arm. Since no differences were observed between the two T arms, a pooled analysis is presented. <h3>Conclusion</h3> Differences in SVR rates among IL28B CC, CT and TT patients were only evident when the three patient subpopulations were pooled, however, SVR among CT and TT patients were still high. In this retrospective analysis, IL28B genotype did not contribute to outcome prediction in prior treatment-experienced patients treated with a telaprevir-based regimen and thus, may be of limited utility in this setting.
Analyzing Hospital Mortality
Authors: Jesse Green
Journal: JAMA (1991)

Consumers and payers increasingly demand data with which to evaluate health care providers. While publication of risk-adjusted hospital-specific death rates is one response, debate continues over whether higher than predicted mortality is a warning about quality of care or rather a reflection of a hospital's atypical patient population. To help inform this debate, we compared the characteristics of Medicare patients discharged from 187 hospitals that the Health Care Financing Administration (HCFA) had labeled "high-mortality outliers" with those of Medicare patients from 5373 hospitals not so designated. Hospitals were most likely to be flagged as high-mortality outliers by HCFA when they had large shares of very elderly patients (age ≥85 years), patients with high-risk diagnoses, or patients requiring nursing home care. After adjustments were made to compensate for these biases, nearly half the hospitals flagged as outliers by HCFA were no longer so designated. Statistics purporting to measure effectiveness of care from hospital death rates should be modified to account for diversity in patient mix. (<i>JAMA</i>. 1991;265:1849-1853)
LECTURES.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Do Clinicians Consider the Results of Binax NOWStreptococcus pneumoniaeUrinary Antigen to Adapt Antibiotic Regimen in Pneumonia Patients?
Authors: Matta Matta, Solen Kernéis, Nesrine Day, Mathilde Lescat, Annie Buu Hoi, Emmanuelle Varon, Laurent Gutmann, Jean-Luc Mainardi
Journal: Clinical Microbiology and Infection (2009)

The BinaxNOW Streptococcus pneumoniae urinary antigen test is a rapid and reliable immunochromatographic test (ICT) for the identification of a pneumococcal aetiology of pneumonia. The aim of this study was to evaluate the attitude of clinicians in their everyday practice towards prescription of the ICT and the impact of its results on the adaptation of the antibiotic therapy when pneumonia is suspected. From October 2007 to March 2008, we prospectively evaluated 541 consecutive inpatients for whom the ICT was performed in our institution. Of the 541 patients evaluated, only 233 (43%) were suspected by the treating physicians to have a pneumonia, 58 of whom had a positive ICT result. Among these 58 patients, four (7%) and 26 (45%), respectively, were treated with amoxycillin monotherapy before and after the ICT result had been obtained (p <10(-4)). Although a positive ICT result led to a rise in the proportion of patients treated with amoxycillin alone, a large number continued to be treated with broader-spectrum antibiotics. These results suggest that prescription monitoring of the ICT should be implemented along with encouragement to adhere more strictly to treatment guidelines.
Total Urinary Follicle Stimulating Hormone as a Biomarker for Detection of Early Pregnancy and Periimplantation Spontaneous Abortion
Authors: Qing Qiu, James W. Overstreet, Heather Todd, Steven T. Nakajima, Dennis R. Stewart, Bill L. Lasley
Journal: Environmental Health Perspectives (1997)

Total concentrations of follicle stimulating hormone (FSH) were evaluated in daily urine samples from conceptive and nonconceptive menstrual cycles by measurement of the FSH beta subunit following treatment of the samples to dissociate the FSH heterodimer. Samples were self-collected by normal subjects during cycles in which daily blood samples also were obtained. Daily blood and urine specimens were collected prospectively from 10 subject in conceptive cycles, which led to normal pregnancies, and from 10 subjects with bilateral tubal ligations to provide control samples form nonconceptive cycles. Mean serum and urinary FSH concentration profiles wer parallel in both groups following ovulation and during he first 9 days of the luteal phase. Mean values for both serum and urinary FSH rose significantly above the postovulatory baseline by 10-12 days following the midcycle luteinizing hormone (LH) peak in nonconceptive cycles, but did not rise at any time following ovulation during conceptive cycles. Following regression analysis of the changing FSH concentration between days 9-14 post-LH surge in conceptive cycles, a slope of </= 0.02 ng FHS/mg creatinine/day was selected as a cutoff point to identify conceptive cycles. There was a high concordance between the day of LH peak in serum and the day of FSH peak in urine. Therefore, in applying the algorithm, the day of FSH peak in urine was used to determine the days for which the FSH slope would be calculated, i.e., days 9-14 post-FSH peak in urine. The sensitivity and specificity of the change in urinary FSH concentrations to detect pregnancy in a different set of 55 cycles were found to 88.9% and 89.3%, respectively. All six cases of early fetal loss in the sample set were correctly identified. These results suggest that urinary FSH can be used as an additional biomarker for the verification of early pregnancy in prospective epidemiological studies in which early fetal loss is a suspected outcome.
Abstract 15416: Impact of Acute Hyperglycemia on Microvascular Damage and Long-term Clinical Outcomes in Patients With ST-elevation Myocardial Infarction
Authors: Tetsuo Horimatsu, Kenichi Fujii, Masashi Fukunaga, Machiko Nishimura, Ten Saita, Akinori Sumiyoshi, Hiroto Tamaru, Kenji Kawai, Masahiko Shibuya, Masaharu Ishihara, Tohru Masuyama
Journal: Circulation (2015)

Introduction: We have recently reported the cause of microcirculatory damage after percutaneous coronary intervention (PCI) in ST-segment elevation myocardial infarction (STEMI) patients can be evaluated by analyzing the thermodilution-derived coronary blood flow pattern (CBFP), and only the capillary destruction pattern was associated with poor mid-term clinical outcomes. In this study, we extend our research on the contribution of acute hyperglycemia on microcirculatory damage and long-term clinical outcomes in STEMI patient. Methods: Ninety-seven consecutive STEMI patients undergoing primary PCI were prospectively enrolled. Using a pressure sensor/thermistor-tipped guidewire, CBFP was assessed from the thermodilution-curves immediately after successful PCI. All patients were classified into 3 groups according to the shape of thermodilution curve: no microvascular damaged group (n=47), arteriole microemboli group (n=33), or capillary destruction group (n=17). Blood glucose levels were measured on admission. Major adverse cardiac events (MACE) were defined as a composite of cardiac death, myocardial infarction, and heart failure rehospitalization within 3 years. Results: Mean admission glucose level was significantly higher in the capillary destruction group than in the microemboli and no microvascular damaged groups (259±134, 162±66, and 153±60 mg/dL, respectively, p&lt;0.0001). These findings were similar when the analysis was limited to non-diabetic patients. The incidence of MACE was also higher in the capillary destruction group compared with the microemboli and no microvascular damaged groups (71, 19, and 16%, respectively, p&lt;0.0001). On multivariate Cox regression analysis, the capillary destruction pattern was the independent predictor of MACE (hazard ratio, 9.41; 95%CI 2.28-38.8; p=0.001). In the multivariate logistic regression analysis, higher glucose level on admission remained as an independent risk factor of the capillary destruction pattern (per 10mg/dL increase, odds ratio, 1.10; 95%CI 1.10-1.22; p=0.002). Conclusions: Hyperglycemia on admission increases the risk of microvascular damage secondary to the capillary destruction and subsequent poor long-term clinical outcomes in STEMI patients.
Possible multicentric occurrence of hepatocellular carcinoma: A clinicopathological study
Authors: K Takenaka
Journal: Hepatology (1994)

To assess the features of multicentric occurrence in hepatocellular carcinoma, we analyzed 10 of 72 patients (14%) who had undergone hepatic resection for hepatocellular carcinoma from May 1989 to October 1992 both clinically and pathologically. The multicentric occurrence of hepatocellular carcinoma was defined among the simultaneously detected small tumors as (a) at least one tumor consisting of extremely well-differentiated (grade I) hepatocellular carcinoma growing in a replacing pattern or (b) one of a group of hepatocellular carcinomas growing in an area of adenomatous hyperplasia. Of the 10 patients, the tumors in 9 were diagnosed as synchronous multicentric hepatocellular carcinomas, whereas the tumor in 1 was considered metachronous. All patients had cirrhosis; one of them had hepatitis B virus infection and nine patients had HCV infection. The inflammatory findings in the parenchyma were determined on the basis of serum enzyme values (AST, 89 ± 27 IU/L; ALT, 96 ± 43 IU/L). One or two tumors in 9 of 10 patients had thin trabecular or trabecular patterns showing replacing growth. In addition, one of the two tumors in two of nine patients was observed growing in areas of adenomatous hyperplasia. Recurrences were found in 4 of 10 patients. The 3-yr disease-free survival rate was 23%. Multiple recurrences were recognized in the two patients, and in the patients who underwent repeat surgery, grade I tumors were also found. Even though these tumors were small and well-differentiated, the recurrence rate was high. Therefore to detect the recurrence of metachronous multicentric hepatocellular carcinoma at an earlier stage, careful follow-up after surgery should be carried out. (HEPATOLOGY 1994;19:889–894.)
Association News
Authors: Carl Henry Davis
Journal: JAMA (1923)

<h3>ANNUAL FELLOWSHIP DUES AND SUBSCRIPTION TO JOURNAL REDUCED</h3> The Board of Trustees of the American Medical Association has authorized the reduction of the annual Fellowship dues and subscription toThe Journalto five dollars per annum, to take effect, January first, 1924. <h3>PRESENTATION OF PAPERS BEFORE SECTION ON OBSTETRICS, GYNECOLOGY AND ABDOMINAL SURGERY</h3><h3>To Fellows:</h3> Any Fellow who would like to present a paper before the Section on Obstetrics, Gynecology and Abdominal Surgery at the Chicago session is requested to write the secretary before Dec. 15, 1923. So far as possible the papers for the final program of this section are selected from the subjects submitted by members for the preliminary program. The preliminary program consists of all papers submitted prior to the date on which the final program must be forwarded to the Secretary of the American Medical Association. A brief outline showing the scope of the paper should
Herpetic Eye Disease Study
Authors: Kirk R. Wilhelmus, Lauren Gee, Walter W. Hauck, Natalie Kurinij, Chandler R. Dawson, Dan B. Jones, Bruce A. Barron, Herbert E. Kaufman, Joel Sugar, Robert A. Hyndiuk, Peter R. Laibson, R. Doyle Stulting, Penny A. Asbell
Journal: Ophthalmology (2020)
Cover Image, Volume 40, Issue 6
Authors: Jan Martel, David M. Ojcius, Cheng‐Yeu Wu, Hsin‐Hsin Peng, Laurent Voisin, Jean‐Luc Perfettini, Yun‐Fei Ko, John D. Young
Journal: Medicinal Research Reviews (2020)

The cover image is based on the Review Article Emerging use of senolytics and senomorphics against aging and chronic diseases by Laurent Voisin et al., https://doi.org/10.1002/med.21702.
Caring for the Underserved
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOARD OF HEALTH CAN NOT RESTRICT MODE OF LAYING FLOOR.
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Masthead: (Adv. Healthcare Mater. 10/2019)
Journal: Advanced Healthcare Materials (2019)

Citizenship: Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups.Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts.
Folic Acid, Vitamins B6 and 12 Do Not Affect Colorectal Adenoma Risk
Journal: JNCI Journal of the National Cancer Institute (2012)

Folic Acid, Vitamins B6 and 12 Do Not Affect Colorectal Adenoma RiskCombined folic acid, vitamin B 6 and vitamin B 12 supplements had no statistically significant effect on the risk of colorectal adenoma among women who were at high risk for cardiovascular disease, according to a study published October 12 in the Journal of the National Cancer Institute.Between 28% and 35% of the U.S. population reported to take dietary supplements containing folic acid, vitamin B 6, and vitamin B 12, and previous in vitro and animal studies have shown that B vitamins combat colorectal carcinogenesis, and some observational epidemiologic studies suggest a 20%-40% reduced risk in individuals with the highest intake of folate, but most randomized controlled trials have focused exclusively on folic acid supplementation.In order to determine the potential effects of folic acid, vitamin B 6 and vitamin B 12 on the risk of colorectal adenoma-a precursor to colorectal cancer-Yiqing Song, M.D., Sc.D., of the Harvard Medical School in Boston and colleagues conducted a study in the Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS), a randomized, doubleblind, placebo-controlled trial which looked at 5,442 female health professionals who were at high risk for cardiovascular disease.The participants in the WAFACS, which took place between April 1998 and July 2005, were randomly assigned to a combination of folic acid, vitamin B 6 and vitamin B 12, or placebo.This analysis included 1,470 WAFACS participants who received a follow-up endoscopy at some point during the 9.2-year follow-up period.